Split History
ETFs Holding TCON »    TCON Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
TRACON Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. Co. is developing its primary product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or in combination with inhibitors of the programmed cell death protein 1 pathway. Co.'s second clinical stage product oncology candidate is TRC102, a small molecule being developed for the treatment of lung cancer and mesothelioma. According to our TCON split history records, TRACON Pharmaceuticals has had 1 split.
TCON split history picture
TRACON Pharmaceuticals (TCON) has 1 split in our TCON split history database. The split for TCON took place on November 08, 2019. This was a 1 for 10 reverse split, meaning for each 10 shares of TCON owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as TRACON Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the TCON split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into TRACON Pharmaceuticals shares, starting with a $10,000 purchase of TCON, presented on a split-history-adjusted basis factoring in the complete TCON split history. TCON split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 01/30/2015
End date: 07/02/2020
Start price/share: $94.00
End price/share: $1.93
Dividends collected/share: $0.00
Total return: -97.95%
Average Annual Total Return: -51.16%
Starting investment: $10,000.00
Ending investment: $205.38
Years: 5.42
Date Ratio
11/08/20191 for 10
TCON is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

TEAR Split History
TECH Split History
TELK Split History
TENX Split History
TEVA Split History
TFX Split History
TGTX Split History
TGX Split History
THC Split History
THRX Split History

Also explore: TCON shares outstanding history

Altus Midstream Company (ATLM)
FS KKR Capital Corp. (FSK)
Groupon (GRPN)
XpresSpa Group, Inc. (XSPA)
Energy Focus, Inc. (EFOI)
The Cushing NextGen Infrastructure Income Fund (SZC)
Teligent, Inc. (TLGT)
Laredo Petroleum, Inc. (LPI)
Global Eagle Entertainment Inc. (ENT)
ToughBuilt Industries, Inc. (TBLT)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

TCON Insider Buying

TCON Split History | www.SplitHistory.com | Copyright © 2013 - 2020, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.